After business hours on Thursday, shares of Elicio Therapeutics fell after the clinical-stage biotechnology company announced an upcoming public offering and data from a study on cancer treatment.
At $4.94, shares were down 28%. At the end of the regular session, they were 6.9% higher at $6.89.
Elicio, a company that makes treatments for cancer, said it started an underwritten public offering of its common stock and common warrants that go with it.
The company also shared early results from a study of ELI-002 7P, an investigational therapeutic cancer vaccine candidate. As of May 24, the data cutoff date, patients who were taking ELI-002 7P at the Phase 2 dose of 4.9 mg AMP-peptide had not yet reached the median disease-free survival endpoint.
